Compare Bitdeer Technologies Group (BTDR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bitdeer Technologies Group vs Regeneron Pharmaceuticals Inc — how do they compare? Bitdeer Technologies Group trades at $8.73 (market cap $2.12B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 39.2× Bitdeer Technologies Group's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Bitdeer Technologies Group pays none. Which is the better fit depends on your goals.
| BTDR | REGN | |
|---|---|---|
Market Cap | $2.12B | $83.19B |
Sector | Technology | Health |
52-Week High | $25.90 | $812.27 |
52-Week Low | $7.28 | $555.51 |
Enterprise Value | $3.88B | $77.90B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTDR trades at $10.88, up 3.42% today, but remains under bearish technical pressure with recent earnings misses. Revenue grew to $620.25M in 2025, yet net income margin turned negative at -26.96% in 2026. The company secured a significant $4.7B AI data center deal, expanding beyond Bitcoin mining. Analyst consensus is strongly bullish with an 81.82% buy rating and a $22.71 price target, suggesting over 100% upside from current levels.
Outlook: High growth potential from AI infrastructure expansion contrasts with profitability challenges and negative cash flow. Risks include execution on new contracts and persistent earnings volatility. The stock offers speculative upside if operational improvements align with analyst optimism.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bitdeer Technologies Group
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
